Subscribe

Berry Genomics

Berry Genomics
SZSE

Berry Genomics is a company specializing in developing and commercializing technologies for life sciences and clinical applications.

OVERVIEW

Categories
Healthcare, Inspection and Diagnostic Equipment, Diagnostic Reagent, AI Medical, Vitro Diagnosis, Molecular Diagnosis, Biopharmaceutical, Medical Instrument, Biotechnology, Genetic Technology, DNA Testing
HQ location
Sichuan
Founded date
May. 1, 2010
IPO date
Apr. 22, 1997
Legal name
Berry Genomics Co., Ltd.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
000710:SZSE
Transaction date
May. 29, 2020
52-week high
CNY 52.50
52-week low
CNY 29.24
Volume
183,793,709
Open
CNY 53.80
Close
CNY 56.90
P/E
-
Market cap
CNY 20.18 billion

ANALYSIS

Berry Genomics's semi-annual report for 2019: Net profit has increased by 70%, want to seize the leading position in the industry?

Berry Genomics mainly sells gene testing services, equipment and reagents based on high-throughput sequencing technology. Its revenue mainly comes from four businesses: medical testing services, reagent sales, equipment sales and basic scientific research services. This coincides with BGI's revenue sources, and it is called "gene dou-heroes" by the industry.

Aug. 28, 2019 · Berry Genomics

Berry Genomics sequencer achieves new breakthrough, the era of large-scale clinical application of gene detection technology has arrived

Berry Genomics's product launch conference was held in Beijing, announcing that the scope of application of its NextSeq CN500 gene sequencer has been changed to become an NGS (next generation sequencing technology) that can be applied to medical institutions and can conduct large-scale clinical genetic testing universal platform immediately .

Jul. 8, 2019 · Berry Genomics

Berry Genomics: How long will it be for the "Millennium Second"?

As of 15:00 on February 20, 2019, the market value of BGI reached CNY 27.69 billion and Berry Genomics was CNY 13.30 billion. The business and revenue structures of the two companies almost overlap.

Feb. 20, 2019 · Berry Genomics

REPORTS

Berry Genomics: Gene sequencing leader, huge potential for early tumor screening

It is estimated that the net profit for 2019-2021 will be 4.09 / 4.65 / 5553 million, with a growth rate of 53% / 14% / 19%. The current stock price corresponding to PE is 31.9 / 28.1 / 23.6x, with a three-year compound growth of about 27%. As a leading company in the field of gene sequencing, the company has significant technological advantages. As the proportion of high-end products for reproductive health testing increases, the gross profit margin has steadily increased, and early cancer screening products are expected to land in 2021, with huge potential space. Based on 25-30 times in 2021, a reasonable valuation of CNY 46.8 ~ 54.6, 27% ~ 48% space from the current stock price of CNY 36.81.

Nov. 21, 2019 · Berry Genomics

贝瑞基因(000710.SZ):Performance in line with expectations, CSCO data for early screening of liver cancer is considerable

It is estimated that the compound revenue growth rate of the company from 2019 to 2021 is about 24.1%, and the profit attributable to the mother is 26.8%. 2019/2020/2021 EPS are CNY 1.19 / 1.36 / 1.54, corresponding PE is 25X / 22X / 19X.

Nov. 1, 2019 · Berry Genomics
  • Company Details
  • Related Companies
  • EO Analysis
Overview
Categories
Healthcare, Inspection and Diagnostic Equipment, Diagnostic Reagent, AI Medical, Vitro Diagnosis, Molecular Diagnosis, Biopharmaceutical, Medical Instrument, Biotechnology, Genetic Technology, DNA Testing
HQ location
Sichuan
Founded date
May. 1, 2010
IPO date
Apr. 22, 1997
Legal name
Berry Genomics Co., Ltd.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
000710:SZSE
Transaction date
May. 29, 2020
52-week high
CNY 52.50
52-week low
CNY 29.24
Volume
183,793,709
Open
CNY 53.80
Close
CNY 56.90
P/E
-
Market cap
CNY 20.18 billion
Analysis

Berry Genomics's semi-annual report for 2019: Net profit has increased by 70%, want to seize the leading position in the industry?

Berry Genomics mainly sells gene testing services, equipment and reagents based on high-throughput sequencing technology. Its revenue mainly comes from four businesses: medical testing services, reagent sales, equipment sales and basic scientific research services. This coincides with BGI's revenue sources, and it is called "gene dou-heroes" by the industry.

Aug. 28, 2019 · Berry Genomics

Berry Genomics sequencer achieves new breakthrough, the era of large-scale clinical application of gene detection technology has arrived

Berry Genomics's product launch conference was held in Beijing, announcing that the scope of application of its NextSeq CN500 gene sequencer has been changed to become an NGS (next generation sequencing technology) that can be applied to medical institutions and can conduct large-scale clinical genetic testing universal platform immediately .

Jul. 8, 2019 · Berry Genomics

Berry Genomics: How long will it be for the "Millennium Second"?

As of 15:00 on February 20, 2019, the market value of BGI reached CNY 27.69 billion and Berry Genomics was CNY 13.30 billion. The business and revenue structures of the two companies almost overlap.

Feb. 20, 2019 · Berry Genomics
Reports

Berry Genomics: Gene sequencing leader, huge potential for early tumor screening

It is estimated that the net profit for 2019-2021 will be 4.09 / 4.65 / 5553 million, with a growth rate of 53% / 14% / 19%. The current stock price corresponding to PE is 31.9 / 28.1 / 23.6x, with a three-year compound growth of about 27%. As a leading company in the field of gene sequencing, the company has significant technological advantages. As the proportion of high-end products for reproductive health testing increases, the gross profit margin has steadily increased, and early cancer screening products are expected to land in 2021, with huge potential space. Based on 25-30 times in 2021, a reasonable valuation of CNY 46.8 ~ 54.6, 27% ~ 48% space from the current stock price of CNY 36.81.

Nov. 21, 2019 · Berry Genomics

贝瑞基因(000710.SZ):Performance in line with expectations, CSCO data for early screening of liver cancer is considerable

It is estimated that the compound revenue growth rate of the company from 2019 to 2021 is about 24.1%, and the profit attributable to the mother is 26.8%. 2019/2020/2021 EPS are CNY 1.19 / 1.36 / 1.54, corresponding PE is 25X / 22X / 19X.

Nov. 1, 2019 · Berry Genomics